NCT04836156View on ClinicalTrials.gov

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2026

Conditions
HER2-negative Early Breast Cancer
Interventions
DRUG

neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer

The choice of chemotherapy is based on the PTC drug sensitivity results.

DRUG

neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer

The choice of chemotherapy is based on the PTC drug sensitivity results.

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER